These targeted therapies have demonstrated their effectiveness in clinical trials, obtaining the approval of the regulatory agencies: encorafenib and cetuximab in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutations, larotrectinib or entrectinib in neurotrophic tyrosine receptor kinase (NTRK) fusions, nivolumab/ipilimumab or pembrolizumab in deficient mismatch repair/microsatellite instability-high and high tumor mutation burden [12,13,14,15,16,17]. This evidence concerns the gene BRAF and neoplasm.